Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 23, 2007

Rentschler Adds Two 500-L Manufacturing Suites as Part of Expansion Project

  • Rentschler Biotechnologie reports that it has commissioned two new GMP manufacturing suites. Both systems will be used to produce therapeutic proteins and mAbs.

    The new fermenter lines with 500-L working volume each are sized such that depending on the respective requirements, different cell culture processes can be run, according to the company. The ensuing protein purification is performed in two suites upstream and two suites downstream of the obligatory virus inactivation.

    Rentschler also plans to add two new 2,500-L multiprocess fermentation suites in mid-2008. Both can optionally be used to run perfusion processes. The expansion project as a whole—the two 500-L and two 2,500-L systems—comprises a new laboratory building, a central energy station, a logistics space as well as additional facilities for sterile filling of syringes and injection vials.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »